According to our recent payer coverage analysis for schizophrenia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT’s team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for schizophrenia treatments shows that under the pharmacy benefit, about 39% of the lives under commercial formularies are covered without utilization management restrictions.

Trends: There is a shift towards more integration of Medicaid benefits into managed care contracts, as well as a slight decline in the use of carve-out financing.